Advaxis, Inc. (NASDAQ:ADXS) CFO Sara Bonstein sold 5,224 shares of the stock in a transaction on Wednesday, January 3rd. The stock was sold at an average price of $3.18, for a total value of $16,612.32. Following the completion of the transaction, the chief financial officer now owns 229,237 shares in the company, valued at $728,973.66. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Sara Bonstein also recently made the following trade(s):

  • On Monday, November 6th, Sara Bonstein sold 3,862 shares of Advaxis stock. The stock was sold at an average price of $3.30, for a total value of $12,744.60.
  • On Thursday, November 2nd, Sara Bonstein sold 12,734 shares of Advaxis stock. The stock was sold at an average price of $3.19, for a total value of $40,621.46.

Shares of Advaxis, Inc. (NASDAQ:ADXS) traded up $0.10 during trading hours on Wednesday, reaching $3.20. The company’s stock had a trading volume of 996,951 shares, compared to its average volume of 1,116,800. Advaxis, Inc. has a fifty-two week low of $2.71 and a fifty-two week high of $10.06. The company has a market cap of $131.00, a PE ratio of -1.39 and a beta of 1.91.

Advaxis (NASDAQ:ADXS) last issued its quarterly earnings data on Wednesday, December 20th. The biotechnology company reported ($0.57) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.02). Advaxis had a negative net margin of 776.63% and a negative return on equity of 114.00%. The company had revenue of $1.76 million for the quarter, compared to the consensus estimate of $3.05 million. sell-side analysts anticipate that Advaxis, Inc. will post -2.36 earnings per share for the current year.

A number of large investors have recently modified their holdings of ADXS. Voya Investment Management LLC lifted its stake in Advaxis by 20.3% during the 2nd quarter. Voya Investment Management LLC now owns 17,612 shares of the biotechnology company’s stock valued at $114,000 after acquiring an additional 2,975 shares in the last quarter. PNC Financial Services Group Inc. lifted its stake in Advaxis by 18.2% during the 2nd quarter. PNC Financial Services Group Inc. now owns 26,000 shares of the biotechnology company’s stock valued at $168,000 after acquiring an additional 4,000 shares in the last quarter. Stonebridge Capital Management Inc. lifted its stake in Advaxis by 88.7% during the 3rd quarter. Stonebridge Capital Management Inc. now owns 42,650 shares of the biotechnology company’s stock valued at $179,000 after acquiring an additional 20,045 shares in the last quarter. State of Wisconsin Investment Board bought a new position in Advaxis during the 2nd quarter valued at $201,000. Finally, The Manufacturers Life Insurance Company lifted its stake in Advaxis by 10.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 31,431 shares of the biotechnology company’s stock valued at $204,000 after acquiring an additional 2,969 shares in the last quarter. Institutional investors and hedge funds own 41.65% of the company’s stock.

ADXS has been the topic of a number of recent research reports. Cantor Fitzgerald set a $19.00 target price on Advaxis and gave the stock a “buy” rating in a report on Thursday, December 28th. HC Wainwright set a $23.00 target price on Advaxis and gave the stock a “buy” rating in a report on Wednesday, December 27th. BidaskClub upgraded Advaxis from a “hold” rating to a “buy” rating in a report on Saturday, September 9th. Finally, ValuEngine upgraded Advaxis from a “strong sell” rating to a “sell” rating in a report on Friday, September 8th.

ILLEGAL ACTIVITY NOTICE: “Sara Bonstein Sells 5,224 Shares of Advaxis, Inc. (ADXS) Stock” was published by American Banking News and is owned by of American Banking News. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.americanbankingnews.com/2018/01/03/sara-bonstein-sells-5224-shares-of-advaxis-inc-adxs-stock.html.

About Advaxis

Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.

Insider Buying and Selling by Quarter for Advaxis (NASDAQ:ADXS)

Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.